Certara Inc (CERT)
Certara, Inc. is a healthcare technology company focused on biosimulation and model-informed drug development. Through its subsidiaries, the company provides software and technology-enabled services used in drug discovery, preclinical and clinical research, regulatory submissions, and market access across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Its offerings include the Simcyp biosimulation platform, Phoenix software for pharmacokinetic, population modeling, and cloud-based analysis, and a range of Chemaxon tools for chemical search, compound registration, design, and drawing. Certara also supplies data automation and validation software through Pinnacle 21, along with solutions for regulatory writing and submissions management such as CoAuthor and GlobalSubmit. Founded in 2008, Certara is headquartered in Radnor, Pennsylvania.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CERT
|
$11.33
|
34.6% Upside
|
Undervalued
|
$8.34
|
-1.0% Downside
|
Fair
|
Good
|
0.0%
|
November 11, 2026
|
1.3x
|
3.0x
|
1.284 B
|
1.401 B
|
18.7%
|
73.4%
|
3.1
|
-357.2%
|
